Fr519 VEDOLIZUMAB IS SUPERIOR TO ANTI-TUMOR NECROSIS FACTOR AGENTS AS A FIRST-LINE BIOLOGICAL AGENT BUT NOT AS A SECOND-LINE BIOLOGICAL AGENT IN MODERATE TO SEVERE ULCERATIVE COLITIS